GB Sciences Company Insiders
| GBLX Stock | USD 0.0005 0.0001 25.00% |
GB Sciences employs about 3 people. The company is managed by 5 executives with a total tenure of roughly 15 years, averaging almost 3.0 years of service per executive, having 0.6 employees per reported executive. Break down of GB Sciences' management performance can provide insight into the company performance.
| John Poss President President, CFO and COO |
GBLX |
GB Sciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.2082) % which means that it has lost $0.2082 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (50.9796) %, meaning that it created substantial loss on money invested by shareholders. GB Sciences' management efficiency ratios could be used to measure how well GB Sciences manages its routine affairs as well as how well it operates its assets and liabilities.GB Sciences Workforce Comparison
GB Sciences is rated # 4 in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 508. GB Sciences maintains roughly 3.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.
GB Sciences Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. GB Sciences Price Series Summation is a cross summation of GB Sciences price series and its benchmark/peer.
GB Sciences Notable Stakeholders
A GB Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GB Sciences often face trade-offs trying to please all of them. GB Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GB Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John Poss | President, CFO and COO | Profile | |
| Krin Kuethe | VP Cultivation | Profile | |
| Gary Esq | Securities Sec | Profile | |
| Zach Swarts | Chief CFO | Profile | |
| MBA MBA | Chief Board | Profile |
About GB Sciences Management Performance
The success or failure of an entity such as GB Sciences often depends on how effective the management is. GB Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GBLX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GBLX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada. Growblox Sciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Please note, the imprecision that can be found in GB Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of GB Sciences. Check GB Sciences' Beneish M Score to see the likelihood of GB Sciences' management manipulating its earnings.
GB Sciences Workforce Analysis
Traditionally, organizations such as GB Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GB Sciences within its industry.GB Sciences Manpower Efficiency
Return on GB Sciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 177K | |
| Net Loss Per Executive | 106.2K | |
| Working Capital Per Employee | 293.7K | |
| Working Capital Per Executive | 176.2K |
Additional Tools for GBLX Pink Sheet Analysis
When running GB Sciences' price analysis, check to measure GB Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GB Sciences is operating at the current time. Most of GB Sciences' value examination focuses on studying past and present price action to predict the probability of GB Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GB Sciences' price. Additionally, you may evaluate how the addition of GB Sciences to your portfolios can decrease your overall portfolio volatility.